EvolusEOLS -0.57%71 OCF Margin % is -13.61% as of Mar. 2026. GuruFocus rates EOLS with a GF Score™ of 71/100 and a GF Value™ of $13.59 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 959 Drug Manufacturers companies, Evolus ranks worse than 83.42% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Evolus's Cash Flow from Operations for the
three
months ended in Mar. 2026 was $-10.0 Mil. Evolus's Revenue for the
three
months ended in Mar. 2026 was $73.1 Mil. Therefore, Evolus's OCF Margin % for the quarter that ended in Mar. 2026 was -13.61%.
The historical rank and industry rank for Evolus's OCF Margin % or its related term are showing as below:
EOLS'
s OCF Margin % Range Over the Past 10 Years
Min: -267.38 Med: -33.5 Max: -6.76
Current: -12.12
During the past 11 years, the highest OCF Margin % of Evolus was -6.76%. The lowest was -267.38%. And the median was -33.50%.
EOLS's OCF Margin % is ranked worse than 83.42% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs EOLS: -12.12
Evolus OCF Margin % Related Terms
Evolus OCF Margin % Historical Data
* Premium members only.
The historical data trend for Evolus's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Evolus's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus (EOLS) has a OCF Margin % of -13.61% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Evolus and its competitors. According to the industry distribution chart, Evolus ranks #800 out of 959 companies in the Drug Manufacturers industry, placing it in the top 83.4%.
Is Evolus' OCF Margin % too high?
Evolus' current OCF Margin % is -13.61%. Based on the distribution chart, Evolus ranks #800 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evolus has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' OCF Margin % compare to EBS and ELTP?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #800 out of 959 companies for OCF Margin %. This places Evolus in the lower half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Evolus and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolus's current OCF Margin % is -13.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.59, compared to a current price of $6.93 — trading 49% below its estimated fair value. The current OCF Margin % is -13.61%. Evolus' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Evolus (EOLS), the current OCF Margin % is -13.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $6.93 is trading 49% below its estimated GF Value™ of $13.59.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
OCF Margin %: -13.61%
GF Value™: $13.59 vs. price of $6.93 (49% below fair value)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
71GF Score
Get the complete analysis for EOLS
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 
